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Treatment Team Addresses Needs
of the Dying Patient
Despite the progress made in cancer treatment, for some
cancer patients disease has advanced too far for cure or no
cure is available. Neurosurgeon Richard Moser, M.D.,
sees patients who have had to face this hard fact, and he is
concerned about the quality of the months and weeks that
remain for them. Some have become alienated from family
members; others worry about the financial burden that
health care has placed on the family. For many, the
physical and the emotional pain associated with death can
be overwhelming.
It is critical that all members of the treatment team
attempt to address the physical, emotional, and psychological needs of the terminally ill. Depending on the type
of support these patients are given, dying can be a time of
reconciliation and peace, or it may mean despair and pain.
"With all the opportunities
we've created for ourselves in
our society, we've also created
many more stresses. Dying is a
time of tremendous anxiety
for many people," said Moser,
who is deputy director in the
Department of Neurosurgery
at The University of Texas
M. D. Anderson Cancer
Center. When efforts to cure
Richard Moser
the patient have become (utile,
he helps the patient and family accept the fact of imminent death. "This is the most important thing going on
in that family's life," Moser said. "I can certainly make it
important to me."
Facing death is an awesome task for anyone, admits
Porter Storey, M.D. Storey is director of The Hospice at
the Texas Medical Center, a facility to which some M. D.

Anderson Cancer Center patients are referred when they
opt for hospice care. Even health care providers can have
difficulty accepting the fact that the patient's death is
approaching, said Storey, who is also adjunct assistant
professor of medicine in M. D. Anderson's Department
of Medical Oncology. Preparing for death reflects
"neither resignation on the part of the patient, nor
defeatism or neglect on the part of the doctor. It is the
unique period in the patient's illness when defeat in living
can be gradually converted into a positive achievement
in dying," Storey said .

Storey has strong feelings about providing the patient
with "honest information" about the terminal prognosis.
"Usually it is obvious to the patient that he or she is
getting worse," he said. "To encourage the patient to
hang on to that 'one chance in a thousand' is rarely
helpful, and adds to the 'conspiracy of silence' that leaves
the patient feeling isolated and alone."
continued on page 2
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Because pain can be such an overwhelming part
of cancer in the later stages, Storey has also learned
much about pain management. He has found that oral
morphine or other oral analgesics are most effective in
relieving pain symptoms in 80% of his patients. He
describes an adequate dose as one that lasts four hours,
and he recommends that one dose be given before the last
has worn off. In this way, a constant level of analgesic is
maintained in the blood stream at all times, so the patient
does not experience severe pain between doses.
Storey said that his medical training in pain management is typical of that given most physicians. "Most
doctors are not familiar with the large doses that are often
needed to treat cancer pain, and are quite hesitant to
prescribe enough medicine to do the job," said Storey,
who advises physicians to "dose to effect" and to use
feedback from other caregivers to help monitor the
effectiveness of pain medications.

The Concept of Total Pain
Helping the patient accept
imminent death and averting
the conspiracy of silence
requires a concerted effort
by a team of health care
professionals. Social worker
Gail Eldridge, M.S.W., is an
M. D. Anderson treatment
team member who helps the
patient and family through
this time of crisis. The health
Gail Eldridge
care team can be most helpful,
she said, if they understand and address the fear, guilt,
and false hopes that patients and families experience.
These feelings all play a role in the patient's "total
pain"-a concept that Eldridge feels all health care
professionals must understand. In addition to the physical
pain, cancer patients experience many emotional and
psychological problems that exacerbate the overall feeling
of being in pain. When all sources of pain are addressed,
a more peaceful death is possible. "But you can't talk
about the total pain concept without first addressing
physical pain," Eldridge emphasized. "All these other
pains are superseded by physical pain. That has to come
first not only for the patient but for the family too. Family
members cannot address the emotional and psychological
pains if their loved one is in physical pain."

Providing Comfort through Symptom
Management
But how to best alleviate physical pain has traditionally
been wrapped in uncertainty. Because of fears that the
patient might become addicted to pain medications,
standard pain relief consisted of conservative dosages.
Physicians, however, are increasingly realizing that these
concerns are unwarranted ( see "Narcotics and Pain
Control," OncoLog, Vol. 33, No. 3, 1988). According
to Moser, it is essential to titrate to need. "You can test
drug levels, but because people metabolize these drugs
differently, those tests will never provide adequate
results." Moser cautions that, with certain cancers, the
amount of pain medicine required is so great that it can
impair cognitive function; nevertheless, pain relief can be
achieved if the dosage is closely monitored.
"I tell patients that they don't get a merit badge for
suffering," said Moser. He finds that in some cases
involving extensive metastasis palliative surgery may be
an option, thus reducing the need for high doses of pain
medications. "Sometimes the best solution is to fix the
problem, not cover it over with medicines."

Symptom Control through Subcutaneous
Infusion
Some patients experience
severe dysphagia, intractable
vomiting, complete gastric
stasis, bowel obstruction, or
other crises. In such cases,
oral medications are intolerable. Storey recommends
subcutaneous infusion rather
than suppositories for these
patients. "We find virtually
100% patient acceptance of
Porter Storey
subcutaneous infusions, unlike
suppository use, among those who cannot tolerate oral
medications. Morphine levels from subcutaneous infusions are as high as from intravenous infusions-even in
hypotensive patients."
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Storey said that a number of narcotic analgesics can
be administered subcutaneously, but only morphine and
hydromorphone are effective for subcutaneous infusion.
H ydromorphone is six times as soluble as morphine on
a weight-per-volume basis, and it takes about 7 mg of
parenteral morphine to reach the analgesic potency of
l mg of hydromorphone. Since the subcutaneous tissue
has a limited capacity to absorb fluid, hydromorphone
is better if there is a need for very high doses of narcotic
or very low v olumes of drug (as in multiday infusions).
Storey rarely finds that patients require subcutaneous
hydromorphone doses over 200 mg/ day, although
others have reported a range of doses from 40 to
4024 mg/ day.
Subcutaneous infusion has also been extremely
effective in controlling nausea and vomiting. When
oral tablets cannot be tolerated, standard rectal suppositories often provide relief. However, the limited dosage
flexibility and frequent turning of the patient limit the
usefulness of suppositories. Because chlorpromazine
and prochlorperazine are too irritating to subcutaneous
tissues , they are not ·used. There are, however, five
antiemetics that are extremely useful: haloperidol,
metoclopramide, methotrimeprazine, cyclizine,
and hydroxyzine.

and families separate their religious convictions from
their core spiritual beliefs. They may be accepting a
dogma that teaches the image of a negative, wrathful
God and have never really explored their innermost
feelings concerning life and death. Some patients may
have religious beliefs that are different from those of their
families. "They struggle over these convictions," she said.
"These are big issues."
Eldridge finds that it is very difficult for patients with
advanced disease to realistically maintain hopes of cure.

"So often, after some response to chemotherapy, the
patient's hopes rise, and he or she begins to think the
doctor was wrong, that they'll be the one to beat this.
I work to keep their hopes realistic and their lives full."

Providing Comfort through Counseling
Once the p hysical pain is addressed, the health care
team should then focus on psychological and emotional
pain . How these issues are approached often depends on
the num ber of losses the patient and family have already
endured , Eldridge said. "How long has this disease been
going on? How many changes have they had to make
because of it?" are key questions. Have they started off
in middle class and are now in poverty because of the
financial drain? Have family members become alienated?
Are there young children at home? What will happen to
them ? Have they made peace with their religious beliefs?
H ow about their feelings concerning the hereafter? All
these elements can contribute to an overwhelming feeling
of pain, Eldridge said.
"Fear plays a big role in this," she said. She encourages
patients and family members to begin talking about their
fears and express their emotions. The moment she
firs t meets the patients, Eldridge attempts to get them
to talk about the issues behind the fear. She also assists
patients in identifying communication problems with
families to help them reconcile their differences.
One disconcerting attitude she finds is the one that
cancer is a form of "almighty" punishment. "Some
people feel that the patient is dying from cancer because
of some sin they've committed," Eldridge said. She,
along with a hospital chaplain, must help these patients

Holistic, Quality-of-Life Approach is Essential
As patients and families face these issues, Eldridge
can take steps to solve some financial and social problems.
As a social worker, she works with community resource
agencies to ensure that patients' outpatient needs are
met. "If you take a holistic, quality-of-life approach to
care of the dying, you see that there are so many things
that can be done to make life better for them." It can
mean calling the children's school counselor to explain
a parent's condition. It can mean making arrangements
for the patient's discharge, such as calling churches to
see if a member can help with respite care; arranging
for Meals on Wheels; procuring equipment such as
hospital beds or oxygen; or arranging transportation
from hospital to home.
For one family with no insurance and very little
income, she referred them to the Texas Department
of Human Services for food stamps and to the Social
Security Administration to apply for disability income
and Supplemental Social Security Income. With those
resources established, the family qualified for state-funded
Medicaid. Without this assistance, the patient would
continued on page 4
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with the patient at home,
M. D. Anderson provides
regular classes on such basic
care skills as monitoring bowel
and bladder func tion, mouth
care, infection recognition,
skin care, fluid balance maintenance, and chemotherapy
administration. A detailed
outline of care instructions is
also provided. The patient is
Joye Rozas
discharged only when staff
feels comfortable that the family can provide in-home
care, Rozas said.
In some cases, nursing support services provided by
home health care agencies will be necessary to assist
families in providing care. The discharge planning staff
matches the patient's needs with an appropriate agency.
Such home support agencies as the Visiting Nurse Association have long provided various services for dying
patients in some communities. A visiting nurse can check
vital signs, monitor medication, and change dressings.
Home .health aides are also available to shampoo hair,
bathe the patient, and take care of personal needs.
With in-home care, health care costs are reduced,
and the patient receives the emotional support that is so
important for terminally ill patients. According to Storey,
"it is remarkable how much medical care can be effectively
handled at home if the resources are available." In order
to provide effective care, symptoms must be well controlled by simple means, usually tablets or suppositories.
Also, families must get enough professional support to
allow them to be effective caregivers.

have had a difficult time managing the obligatory
blood tests needed in order to continue chemotherapy
and would not have qualified for the support services
she later needed for in-home care after discharge.
M. D. Anderson's Department of Social Services funded
an ambulance transfer to get her back home, where she
wanted to be in her last days.
Obviously, some problems are not solvable, said
Eldridge. It then becomes important to help patients
accept the decisions that were made and accept the
priorities that were then and are still being set. Sometimes
there are value conflicts because the limited amount of
money that was available was spent on health care that did
not work. "You can't 'Monday morning quarterback' a
decision made two years ago that set the ball in motion,"
Eldridge said. "That's part of coming to grips with
dying." To provide perspective on the situation, she
sometimes asks a patient to consider what would have
been done if their spouse had faced the same prognosis.
"They always say, without hesitation, that they would
have given it their best shot." This counseling approach
helps them put aside some of the guilt they feel.

Inpatient Hospices Available
Inpatient facilities such as nursing homes are
sometimes an option when the nursing needs are more
intensive and when the patient has a funding source.
Patients are only referred to agencies that are approved
by the patient's funding source-whether Medicare,
Medicaid, or insurance.
Unfortunately, many health care providers do not
specialize in problems of the dying cancer patient and
thus have difficulty determining the kind of medical care
to administer, Storey said. Some patients may receive too
much acute care and spend their final months recovering
from "futile attempts to stop their advanced illness."
Other patients may suffer from too little attention to
their pain, nausea, or dyspnea.
In the past decade, growing numbers of health
care practitioners have become aware of the advantages
of hospice care as an option for the dying patient.
Hospice care professionals are dedicated to controlling

Providing Continuity of Nursing Care after
Discharge
The nursing care that is required after discharge is
coordinated largely by nnrsing staff Patients require
various degrees of nursing care, and it is up to the discharge planning nurse to help the family determine
whether care can be provided at home, whether outside
agencies will be needed as intermittent support services to
home care, or whether an inpatient facility will be necessary. "We present the family with the options and help
them decide what is best for the situation," said discharge
planner Jaye Rozas, R.N.
Before a family decides to attempt in-home care, "they
must know just how much nursing care will be required
and decide how much they can handle," Rozas said.
So that the family member or caregiver will feel confident
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these distressing symptoms and also addressing the
patient's emotional concerns. This allows a cancer
patient's final days to be some of his richest, Storey said.
The structure of hospice programs varies considerably.
Among the 1400 hospices in the United States today, the
majority provide a range of nursing support services for
patients dying at home; only 35 hospices offer their own
inpatient facilities that provide a caring environment in
which the physical and emotional needs of the terminally
ill can be met. Other hospice programs have contracts
with hospitals and nursing homes to provide hospice care.
The hospice home care arrangement is similar to any
in-home care setting, in which family provides the basic
patient care; however, supportive nursing services are
usually provided by a health care agency with professionals
trained in the needs of the dying. Social workers are available to provide counseling and address the psychological
and emotional concerns of the dying. Hospice nursing
staff also are better trained in attending to the pain needs
of these patients.
There are situations in which in-home care just does
not work, Storey said . Inpatient hospice facilities have
been developed fo r patients whose symptoms have grown
beyond the capabilities of the family. While inpatient
hospices provide m edical assistance for symptom control,
"more medical technology is not necessarily considered to
be better. People don't want to see their family members
die in the intensive care unit with all sorts of tubes in
place," Storey said. Inpatient hospices are generally
described as "loving, home-like" facilities where social
workers and nursing staff focus their attention on making
the patient comfortable. At The Hospice at the Texas
Medical Center, for example, a comprehensive team
approach to hospice care has been implemented. When
nurses, social worker, chaplain, home health aides,
bereavement counselor, and volunteers all get involved
with the patient and family, it is possible to more completely address all the patient's needs, Storey said.

Vol. 35, No. 3

needs the type of symptomatic/supportive care that
hospices provide. She would also like to see more services
made available for indigent patients who are dying. The
discharge planning team encounters patients who have
no insurance, do not qualify for Medicare or Medicaid,
and sometimes have no family to depend on for even
minimal care. Nursing homes and many home care
agencies will not accept patients without some form
of financial support. And some patients are from small
rural communities where quality health care resources
are at a minimum.

Rozas recalls one patient who had undergone extensive
head and neck surgery and was returning home for care.
Both his income and the community resources were
limited, so his wife accepted responsibility as caregiver.
Before he was discharged, she received training from
M. D. Anderson staff to provide basic nursing care.
However, it became clear to her and to the nursing
staff that she would not be able to handle all his care
needs. They had no insurance and qualified for neither
Medicare nor Medicaid, so an inpatient facility was out
of the question, and research conducted by the discharge
planning staff revealed that community home health care
resources were nonexistent.
"These patients can 'fall through the cracks' unless the
entire treatment team-social worker, physical therapist,
dietitian, clinical nurse specialist, chaplain-tackles the
problem of developing a plan for the patient's discharge,"
Eldridge said. In this case, an M. D. Anderson chaplain
contacted a local church, who in turn found a volunteer
who could help. The patient's emotional fears then began
to surface. Both he and his wife did not want a stranger
to see him because of his facial disfigurement. Rozas
counseled and reassured them, and they finally accepted
the help; "We don't ever give up," she concluded. ■

The Future for Care of the Dying
Health care professionals such as Moser, Eldridge,
Rozas, and Storey all advocate the holistic approach to
care of dying patients. Though hospice programs are
not yet available in every community, their numbers are
growing. "There are some pretty innovative hospiceoriented programs available in nursing homes," Eldridge
said. "Hospice, after all, is not a place, it is a care
approach." Many more home health agencies have
adopted the holistic approach.
Eldridge perceives a lack of community resources for
the patient who is undergoing palliative treatment and is
expected to live longer than six months. Very often, she
said, that person does not qualify for hospice care, yet

Physicians who desire additional information may write Gail Eldridge,
M.S.W., Department of Social Work, Box 103; Richard Moser, M.D.,
Department of Head and Neck Surgery, Box 69; or Joye Rozas, R.N .,
Department of Nursing, Box 82; The University of Texas M. D . Anderson
Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, or
call (713) 792-6195 (Eldridge), 792-6920 (Moser), or 792-7100 (Rozas ).
Porter Storey, M.D., can be reached at The Hospice at the Texas Medical
Center, 6205 Almeda, Houston, Texas 77021, (713) 467-7423.
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Fludarabine

continued from page 8
cytotoxic chemotherapy. Patients initially received
25 mg/m 2/day for five days every three weeks, but the
dosage was later revised to 30 mg/m 2/ day for five days
every four weeks. Of the 39 patients who responded
(57%), nine achieved a complete response (13%). This
response rate of 57% was a marked improvement over
multiagent protocols, whose response rates generally
range from 25 to 30%.

effective chemotherapeutic agents, have slowed progress
in treatment research. "Frequently, CLL is diagnosed in
patients who are in their 70s or 80s. These patients are
already susceptible to other fatal conditions such as stroke,
heart failure, or second cancers, so they die of other diseases," Keating said. "And because CLL grows slowly,
many patients may live eight to ten years, even without
treatment, so it takes at least that much time to gather
any meaningful survival data."

Hope for Patients under the Age of 55 Years
Consequently, previously untreated patients can now
choose a less toxic but equally effective form of therapy,
and previously treated patients can elect treatment that is
not only-less toxic but more effective than conventional
regimens. ·, Moreover, fludarabine may provide hope to a
subset of CLL patients who at present have no curative
treatment options: patients under the age of 55 who have
early stage disease.
"It is frustrating that there is no treatment for early
stage CLL ( elevated white cell count with no evidence
of enlarged lymph nodes, liver, or spleen and no evidence
of bone marrow failure)," Keating said. "In fact, some
studies have shown that immediate treatment of CLL with
chemotherapy actually decreases survival because patients
develop second cancers. We therefore must defer treatment until the disease progresses."
What do you tell a 40-year-old patient who has a
disease that will kill him within eight to ten years, and
yet his disease is usually not treated until it gets worse?
The answer may lie in combining fludarabine with
autologous bone marrow transplantation.
"I think that will be a very important direction,"
Keating said. "CLL cells can be distinguished from
normal bone marrow cells by using monoclonal antibodies. After inducing remission with fludarabine, we
could then extract the marrow, use monoclonal antibodies
to purge the marrow of leukemic cells, and store it for
future use. So for patients under the age of 55 years with
early stage disease, this approach may be one way of
altering CLL's inevitably fatal course."
Fludarabine with autologous bone marrow transplantation may also play a role in overcoming another
major obstacle to curing CLL: revitalizing the immune
system, which is permanently damaged even if chemotherapy induces a response.
"CLL carries a double threat: the malignancy itself and
the immune deficiency. CLL severely impairs the function of humoral immunity (mediated by B cells) and
cellular immunity (mediated by T cells). We know that
the B cells are impaired because the level of antibodies in
the serum is low, but trying to isolate the role of T cell
impairment has been much more difficult," Keating said.

Fludarabine as Effective as Multiagent Protocols
Whether fludarabine will play a role in curative regimens thus will require several more years of research;
nevertheless, patients now have an alternative to standard
CLL therapy, which usually consists of several courses of
alkylating agents such as chlorambucil or cyclophosphamide, sometimes combined with prednisone or vincristine.
Standard therapy has induced partial response rates as
high as 75%, but disease recurs and patients become
resistant to further therapy. Median survival after treatment for advanced disease averages five years.
One encouraging aspect of fludarabine is that it is just
as effective in inducing remission as standard multiagent
protocols and is less toxic. Keating and his colleagues
recently reported a 79% response rate in 33 previously
untreated patients ( Nouvelle Revue Franfaise D
Hematologie 30:461-466; Journal of Clinical Oncology)
in press). They received 30 mg/m 2/day of fludarabine
for five days every four weeks, and 11 of them ( 33%)
achieved a complete response. In 20% of the courses,
patients developed infection or fever, but in terms of
other side effects, fludarabine was remarkably nontoxic.
There was no evidence of neurotoxicity, and patients did
not experience nausea, vomiting, alopecia, or diarrhea.
But perhaps more important is fludarabine's effectiveness in previously treated patients. Keating and his team
have .also treated 68 patients who had received prior
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With most chemotherapy, low neutrophil counts
correlate with febrile episodes, but this is not the case
with CLL patients treated with fludarabine: Neutrophil
counts are often normal when febrile episodes occur.
This would suggest that infections are not related to
myelosuppression and perhaps are solely attributable to
the B cell deficiency. However, the spectrum of infectious
pathogens-]?neumocystis carinii, cytomegalovirus, herpes
simplex, herpes zoster-seen in fludarabine-treated CLL
patients is perplexing. "These infections are more indicative of an abnormality in T cell immunity, such as that
seen in acquired immune deficiency syndrome. Something
seems to be going on with the T cell immunity, but at
present.it's a black box."
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Nevertheless, Keating said that researchers are now
poised to tackle the problem of restoring the humoral
immune response, and to do so they plan to use fludarabine in conjunction with autologous bone marrow
transplantation and with cytokines such as interferon,
interleukin-2, and interleukin-4. "The good thing about
fludarabine is that
it can eliminate all or part of the disease
I
in a large num ber of patients. This has opened up the
next dimension of research. Previously, we had no treatment that could reproducibly eradicate the leukemic cells,
but now that we do, we have the opportunity to restore
the immune response too."
Fludarabine research at the M. D. Anderson Cancer
Center is progressing along several lines. Animal studies
have examined a form of fludarabine that can be given by
mouth. "If the initial results can be applied to man, then
patients will be able to take the drug much more easily,"
Keating said. Other phase I and II studies will examine
combining fludarabine with chlorambucil, doxorubicin,
cytosine arabinoside, mitoxantrone, and interferon.

Editorial Board

David M.Gershenson, M.D.; Frankie A. Holmes, M.D.;
Raymond E. Meyn, Jr., Ph.D.; William K. Plunkett, Jr., Ph.D.;
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Published quarterly by the Department of Scientific Publications, Division of
Academic Affairs, The University of Texas M. 0. Anderson Cancer Center,
1515 Holcombe Boulevard, Houston, Texas 77030. Made possible by o gift horn
the late Mrs. Horry C. Wiess and grants from 1he University Cancer Foundation.

Keating stresses that the results are preliminary and
the study samples small; nevertheless, they point to
fludarabine's versatility and suggest that in years to come
this agent may play a significant therapeutic role in a
variety of diseases.
Fludarabine is still considered an experimental drug,
so its availability is restricted to research institutions like
M. D. Anderson, but in certain cases physicians can acquire
the drug from the National Cancer Institute through a
"class C" mechanism. "We obviously feel that a patient
would benefit from our expertise at M. D. Anderson, but
it's important for physicians to know that, for patients
who cannot come or do not want to come to our institution, fludarabine can be obtained from the National
Cancer Institute. So for patients refractory to conventional CLL therapies, fludarabine is a viable and accessible
treatment option, regardless of where that patient lives." ■

Fludarabine Also Effective in Other,
Rarer Diseases
Keating added that in addition to CLL, fludarabine
is showing promise for treating other diseases. "A preliminary study has shown that fludarabine was active
against Waldenstrom's macroglobulinemia ( 5 of 11
patients responded) and prolymphocytic leukemia (6 of
17 patients). Other studies have shown a 62 % response
rate ( 13 of 21 patients) against follicular lymphoma, a
33% response rate (4 of 12) against small cell lymphocytic
leukemia, an 80% partial response rate ( 4 of 5) against
follicular mixed cell lymphoma, and a 100% partial response rate against follicular large cell lymphoma (2 of 2 ).

Physicians who desire additional information may write
Michael J. Keating, M.B ., B.S., Department of Hematology, Box 55,
The University of Texas M. D. Anderson Cancer Center, 1515
Holcombe Boulevard, Houston, Texas 77030, or call (713) 792-2747.
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Fludarabine Opens a New Dimension in Chronic
Lymphocytic Leukemia Research
Wh

n li t ning to Michael J.
Keating, M.B., B .. , talk about
fludarabin for chronic
lymphoc tic l ukemia ( CLL)
you detect a mixture of reli f
and excitement. Keating chief
Gf-c---l-ini-c---a-l studie---S--i-H th
Department of Hematology
and associate vice president
for clinical in estigation,
Michael J. Keating
remembers \ hen the medical
community almost dismissed fludarabine-initially used
to treat acute leukemia-as too toxic. Phase I and II
acute leukemia studies showed that high-dose fludarabine
had a devastating side effect: severe nerve damage.
"The damage was so distressing that it almost stopped
investigation of the drug," Keating said.
Fortunately, other research on its use at lower doses in
low-grade 1 mphoma and CLL saved fludarabine from

in e tigational obli ·
th
cane r could
to fourfold lo r
morbidity and lim
as almo t v ritt n
for CLL tr atment.
rot:-t-h past----swer.
- ill-ia-m--P-1 u n k ~
Jr., Ph.D. and their
t
of Texas M. D. Ander
much of their research
i
CLL remains elusi
but
m
ti eness of fludarabin not
n
treatment options but al o
second tier of CLL re arch: d termin·
talize the immune s st m \: hi h i in apa
CLL-the most common form of 1
Wes tern v orld-grm slm 1 and oc ur prim ril) in th
elder! . The e t\: o factor in addition to th l k of
continued on page 6
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